This record was last updated November 14, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The study will evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) responses of FMXIN002, an intranasal epinephrine powder, compared with the EpiPen® intramuscular autoinjector, after single and double doses, in healthy adults with a history of allergic rhinitis.